On Nov 06, major Wall Street analysts update their ratings for $Vertex Pharmaceuticals (VRTX.US)$, with price targets ranging from $486 to $600.
J.P. Morgan analyst Jessica Fye maintains with a buy rating, and sets the target price at $503.
Barclays analyst Gena Wang maintains with a hold rating, and maintains the target price at $509.
Evercore analyst Liisa Bayko maintains with a buy rating, and maintains the target price at $515.
TD Cowen analyst Phil Nadeau maintains with a buy rating, and maintains the target price at $525.
Oppenheimer analyst Hartaj Singh maintains with a buy rating, and adjusts the target price from $500 to $540.
Furthermore, according to the comprehensive report, the opinions of $Vertex Pharmaceuticals (VRTX.US)$'s main analysts recently are as follows:
Following Vertex Pharmaceuticals' third-quarter results surpassing consensus and an approximate 1% raise in 2024 revenue guidance at the midpoint, expectations are now set on the forthcoming suzetrigine Phase 2 lumbosacral radiculopathy (LSR) data anticipated by year-end.
The company's strong performance in its cystic fibrosis business demonstrates the ongoing robustness of its primary operations, which is expected to sustain the stock's high valuation. However, the outlook leading into FY25 may present more challenges compared to FY24, with potential data on suzetregine anticipated to confirm efficacy but perhaps not generate significant enthusiasm, and the launches of acute pain treatments and Casgevy possibly experiencing gradual uptake.
Here are the latest investment ratings and price targets for $Vertex Pharmaceuticals (VRTX.US)$ from 8 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月6日，多家華爾街大行更新了$福泰製藥 (VRTX.US)$的評級，目標價介於486美元至600美元。
摩根大通分析師Jessica Fye維持買入評級，目標價503美元。
巴克萊銀行分析師Gena Wang維持持有評級，維持目標價509美元。
Evercore分析師Liisa Bayko維持買入評級，維持目標價515美元。
TD Cowen分析師Phil Nadeau維持買入評級，維持目標價525美元。
奧本海默控股分析師Hartaj Singh維持買入評級，並將目標價從500美元上調至540美元。
此外，綜合報道，$福泰製藥 (VRTX.US)$近期主要分析師觀點如下：
福泰製藥第三季度的業績超過共識，2024年營業收入指引在中點上升約1％，現在市場對即將到來的年底前期待的蘇替林第2期腰骶神經根痛（LSR）數據做出了期望。
公司在囊性纖維化業務方面的強勁表現顯示了其主要業務的持續穩健性，預計將維持高估值的股價。然而，到2025財年的前景可能會面臨比2024財年更多的挑戰，蘇替林的潛在數據預計將確認療效，但可能不會引發很大熱情，急性疼痛治療和Casgevy的推出可能會經歷逐步接受。
以下爲今日8位分析師對$福泰製藥 (VRTX.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
